-
Panitumumab, sold
under the
brand name Vectibix, is a
fully human monoclonal antibody specific to the
epidermal growth factor receptor (also
known as...
- most
common adverse reactions for
sotorasib used in
combination with
panitumumab include rash, dry skin, diarrhea, stomatitis, fatigue, and musculoskeletal...
- (FDA)
updated the
labels of two anti-EGFR
monoclonal antibody drugs (
panitumumab (Vectibix) and
cetuximab (Erbitux))
indicated for
treatment of metastatic...
-
nerve palsy Anti-cancer
treatments such as erlotinib, cetuximab, and
panitumumab,
which block the
function of EGFR (the
epidermal growth factor receptor)...
- often[citation needed]
combined with bevacizumab, aflibercept,
cetuximab or
panitumumab to
improve efficacy and
response rate. In the
short term, irinotecan...
- As of 2006, KRAS
mutation was
predictive of a very poor
response to
panitumumab (Vectibix) and
cetuximab (Erbitux)
therapy in
colorectal cancer. As of...
-
Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab Ranibizumab Rituximab Trastuzumab Monoclonal antibodies...
- 2006: In April,
Amgen acquired Abgenix, the
developer of
Vectibix (
panitumumab), a
treatment developed for
certain patients with
metastatic colorectal...
-
conventional antibodies like
trastuzumab (targeting HER2/neu),
cetuximab and
panitumumab (both
targeting the EGF receptor),
using the BiTE approach. As of 2009[update]...
-
colorectal cancer and
squamous cell
carcinoma of the head and neck.
Panitumumab also
targets the EGFR. It is
approved for the use in the
treatment of...
